# OnCo record anagrelide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/anagrelide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "anagrelide" ;
  schema:name "Anagrelide"@en ;
  schema:description "Anagrelide (Agrylin) is a capsule that lowers dangerously high platelet counts in essential thrombocythaemia and other myeloproliferative neoplasms, reducing the risk of clots and bleeding."@en ;
  schema:url <https://onco.cc/drugs/anagrelide/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anagrelide> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/xagrid>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=anagrelide> ;
  onco:status "approved" ;
  onco:tag "ema-list" ;
  onco:modality "Oral platelet-lowering agent (imidazoquinazoline)" ;
  schema:alternateName "Agrylin / Xagrid" ;
  onco:approval "US 1997: Thrombocythaemia secondary to myeloproliferative neoplasms", "EU 2004: Elevated platelet counts in at-risk essential thrombocythaemia intolerant of or inadequately controlled by current therapy (Xagrid)" ;
  onco:related <https://onco.cc/drugs/hydroxyurea/> ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/nct04285086/> .